SCHEMBL26099409

SCHEMBL26099409

Cn1ccc2cccc(C3CCN(C(=O)OC(C)(C)C)CC3)c21

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.46
THRB P10828 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
NAMPT P43490 1/20 0.44
TP53 P04637 1/20 0.44
SCN9A Q15858 1/20 0.43
STS P08842 2/20 0.43
PDE10A Q9Y233 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
POLB P06746 1/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
JAK3 P52333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395513 0.88 GPR119 (0.46) GPR119THRBKDM4EMAPTNAMPT
SCHEMBL14445218 0.86 GPR119 (0.47) GPR119THRBKDM4EMAPTNAMPT
SCHEMBL5203683 0.81 HTR6 (0.51) GPR119KDM4ESTSPOLB
SCHEMBL23443529 0.81 GPR119 (0.53) GPR119THRBKDM4EMAPTNAMPT
SCHEMBL30368880 0.81 GPR119 (0.53) GPR119THRBKDM4EMAPTNAMPT
SCHEMBL20142785 0.80 CKS1B (0.46) GPR119MAPTNAMPTPOLB
SCHEMBL29361808 0.79 ACLY (0.44) GPR119KDM4ESTS
SCHEMBL26102698 0.79 SCN9A (0.46) GPR119THRBKDM4EMAPTNAMPT
SCHEMBL19284615 0.78 GPR119 (0.55) GPR119THRBKDM4EMAPTTP53
SCHEMBL21885666 0.78 GPR119 (0.55) GPR119THRBKDM4EMAPTNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 US disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 EP disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A GPR119 3223/4885THRB 1489/4885KDM4E 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.